



Universiteit  
Leiden

The Netherlands

**Diagnosis and post-treatment monitoring of schistosomiasis in endemic and non-endemic settings by quantification of schistosome circulating anodic antigen**

Hoekstra-Mevius, P.T.

**Citation**

Hoekstra-Mevius, P. T. (2023, June 27). *Diagnosis and post-treatment monitoring of schistosomiasis in endemic and non-endemic settings by quantification of schistosome circulating anodic antigen*. Retrieved from <https://hdl.handle.net/1887/3626940>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3626940>

**Note:** To cite this publication please use the final published version (if applicable).

5.

Efficacy of single versus four repeated doses of praziquantel against *Schistosoma mansoni* infection in school-aged children from Côte d'Ivoire based on Kato-Katz and POC-CCA: An open-label, randomised controlled trial (RePST)

Pytsje T. Hoekstra<sup>1</sup>, Miriam Casacuberta-Partal<sup>1</sup>, Lisette van Lieshout<sup>1</sup>, Paul L.A.M. Corstjens<sup>2</sup>, Roula Tsonaka<sup>3</sup>, Rufin K. Assaré<sup>4,5,6,7</sup>, Kigbavori D. Silué<sup>4,5</sup>, Aboulaye Méité<sup>8</sup>, Eliézer K. N'Goran<sup>4,5</sup>, Yves K. N'Gbesso<sup>9</sup>, Abena S. Amoah<sup>1,10,11</sup>, Meta Roestenberg<sup>1,12</sup>, Stefanie Knopp<sup>6,7</sup>, Juerg Utzinger<sup>6,7</sup>, Jean T. Coulibaly<sup>4,5,6,7</sup>, Govert J. van Dam<sup>1</sup>

*PLoS Neglected Tropical Diseases* (2020)

## ABSTRACT

### Background

Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated doses of PZQ at short intervals might increase efficacy in terms of cure rate (CR) and intensity reduction rate (IRR). Here, we determined the efficacy of a single versus four repeated treatments with PZQ on *Schistosoma mansoni* infection in school-aged children from Côte d'Ivoire, using two different diagnostic tests.

### Methods

An open-label, randomized controlled trial was conducted from October 2018 to January 2019. School-aged children with a confirmed *S. mansoni* infection based on Kato-Katz (KK) and point-of-care circulating cathodic antigen (POC-CCA) urine cassette test were randomly assigned to receive either a single or four repeated doses of PZQ, administered at two-week intervals. The primary outcome was the difference in CR between the two treatment arms, measured by triplicate KK thick smears 10 weeks after the first treatment. Secondary outcomes included CR estimated by POC-CCA, IRR by KK and POC-CCA, and safety of repeated PZQ administration.

### Principal findings

During baseline screening, 1,022 children were assessed for eligibility of whom 153 (15%) had a detectable *S. mansoni* infection, and hence, were randomized to the standard treatment group (N = 70) and the intense treatment group (N = 83). Based on KK, the CR was 42% (95% confidence interval (CI) 31–52%) in the standard treatment group and 86% (95% CI 75–92%) in the intense treatment group. Observed IRR was 72% (95% CI 55–83%) in the standard treatment group and 95% (95% CI 85–98%) in the intense treatment group. The CR estimated by POC-CCA was 18% (95% CI 11–27%) and 36% (95% CI 26–46%) in the standard and intense treatment group, respectively. Repeated PZQ treatment did not result in a higher number of adverse events.

### Conclusion/significance

The observed CR using KK was significantly higher after four repeated treatments compared to a single treatment, without an increase in adverse events. Using POC-CCA, the observed CR was significantly lower than measured by KK, indicating that PZQ may be considerably less efficacious as concluded by KK. Our findings highlight the need for reliable and more accurate diagnostic tools, which are essential for monitoring treatment efficacy, identifying changes in transmission, and accurately quantifying the intensity of infection in distinct populations. In addition, the higher CR in the intense treatment group suggests that more focused and intense PZQ treatment can help to advance schistosomiasis control.

### Trial registration

[www.clinicaltrials.gov/NCT02868385](http://www.clinicaltrials.gov/NCT02868385).

## AUTHOR SUMMARY

The previously established efficacy of the widely used drug praziquantel (PZQ) against schistosomiasis might have been overestimated due to the use of inaccurate diagnostic methods. Repeated PZQ treatment at short intervals in areas with ongoing transmission could more effectively target non-susceptible schistosomes as they will have matured into drug susceptible worms within a few weeks. In the current study, we aimed to determine the cure rate (CR) of repeated PZQ, measured by the Kato-Katz (KK) technique and the point-of-care circulating cathodic antigen (POC-CCA) test, respectively. An open label, randomized controlled trial was conducted assigning 153 school-aged children with a confirmed *Schistosoma mansoni* infection to two groups, one receiving a single PZQ treatment, while the second group received four repeated PZQ treatments, given at two week intervals. Based on the KK test, the CR was significantly higher after four repeated treatments compared to a single treatment. When using POC-CCA, a diagnostic method that has not been utilized before in studies assessing the efficacy of four repeated PZQ treatments, the CR was much lower, even after four repeated PZQ treatments. Our results indicate that worms are still present after multiple PZQ treatments and that PZQ might be less efficacious than previously published.

## INTRODUCTION

Schistosomiasis remains a public health problem in different parts of the world with an estimated 779 million people at risk of infection and more than 250 million people infected (1,2). The disease is caused by parasitic blood flukes of the genus *Schistosoma*. The three most important species are *S. japonicum* and *S. mansoni* (causing intestinal schistosomiasis) and *S. haematobium* (causing urogenital schistosomiasis) (3,4). To control schistosomiasis, health authorities rely on preventive chemotherapy, that is the large-scale administration of the anthelmintic drug praziquantel (PZQ) to at risk populations without prior diagnosis (5). This strategy has been successful in reducing the prevalence and, most importantly, the intensity of infection, and thereby controlling morbidity (6,7). The burden of schistosomiasis is greatest in school-aged children, generally presenting the highest prevalence and intensity of infection (8). School-aged children are therefore the main target for preventive chemotherapy, consisting of a single 40 mg/kg oral dose of PZQ, as recommended by the World Health Organization (WHO) (5, 9, 10). PZQ is the drug of choice because it is safe and efficacious against the adult stages of all *Schistosoma* species (11). The efficacy of PZQ is typically expressed as a cure rate (CR) and often also as an intensity reduction rate (IRR), both based on pre- and post-treatment data. Reported CRs in school-aged children range between 42% and 79% for *S. mansoni* and between 37% and 93% for *S. haematobium* after a single 40 mg/kg oral dose of PZQ (12–14). Following a closely spaced second dose of PZQ, considerably higher CRs are reported; 91% for *S. mansoni* (12,15,16) and 99% for *S. haematobium* (12).

Most studies reporting on the efficacy of PZQ have used microscopy-based methods, such as urine filtration for *S. haematobium* and the stool-based Kato-Katz (KK) technique for *S. japonicum* and *S. mansoni*. However, these methods lack sensitivity, especially for detection of low-intensity infections (17,18). Hence, reported CRs based on these parasitological methods are

likely an overestimation (19,20). From a public health perspective, the absence or a significant reduction in the number of *Schistosoma* eggs is essential as they are causing morbidity and keep transmission ongoing. However, from an individual health care perspective, worm absence (cure) is more important. It is known that PZQ targets adult worms, therefore a direct determination of PZQ efficacy would be to measure the number of worms instead of eggs (which are usually used as a proxy for worm burden) with a highly accurate diagnostic tool. The field-applicable and commercially available point-of-care circulating cathodic antigen (POC-CCA) urine test, which identifies active worm infections by detection of schistosome CCA in urine, has shown a higher sensitivity for detecting *S. mansoni* infections than the KK technique (20–22). It is now being recommended for surveillance and mapping of prevalence of intestinal schistosomiasis (10,18,21,23).

In addition to the possible overestimation of CRs due to insensitive diagnostic tools, the limited activity of PZQ on immature worms as well as continuing reinfection might have led to an underestimation of the efficacy (24–27). Furthermore, the short metabolic half-life of PZQ might also limit its effectivity (28). In areas with ongoing transmission, where repeated infections and hence the presence of schistosomula in the human body is likely, repeating PZQ treatment a few weeks after the first dose might increase its overall effectiveness for parasitological cure (12,29).

In the current study, we assessed the effect of multiple doses of PZQ on parasite clearance and tolerance in school-aged children from Côte d'Ivoire with a confirmed *S. mansoni* infection. As primary outcome we determined the difference in CR of a single versus four repeated doses of PZQ, measured by the KK technique in stool samples 10 weeks after the first treatment. Secondary outcomes included CR measured by the POC-CCA test, IRR by KK and POC-CCA, and safety of repeated PZQ treatments. Given the paucity of highly effective control measures for schistosomiasis, the results of our study are essential to assess the most optimal PZQ strategy from a public health control and best-care perspective.

## METHODS

### *Ethics statement*

Ethics approval was obtained from the Comité National d'Éthique des Sciences de la Vie et de la Santé de Côte d'Ivoire (CNESVS; reference no. 091-18/MSHP/CNESVS-km, date of approval 27 June 2018), the Direction de la Pharmacie, du Médicament et des Laboratoires de Côte d'Ivoire (DPML; reference no. 99433/MSPH/DGS/DPML/DAR and clinical trial number ECCI00618, date of approval 22 October 2018), and the Ethics Committee of the Leiden University Medical Center in the Netherlands (P16.254, date of approval 11 January 2017). Communities and health authorities were informed on the purpose and procedures of the study. Participating children were informed about the objectives, procedures, and potential risks and benefits of the study using lay terms. Written informed consent was obtained from children's parents or guardians, while children provided oral assent. The trial is registered at ClinicalTrials.gov (registration no. NCT02868385).

### *Study design and participants*

We conducted an open-label, randomized controlled trial with two arms in which children aged 5–17 years from three villages located in the Taabo health district in south-central Côte d'Ivoire (30) were included.

The trial was conducted from October 1, 2018 to January 14, 2019. In the first month of the study (October 2018), children were assessed for eligibility during a baseline screening. Children who were found positive for *S. mansoni* by KK and POC-CCA and egg-negative for *S. haematobium* by urine filtration were eligible. A detailed description of the inclusion and exclusion criteria is provided in the study protocol published elsewhere (31). Eligible children were randomized into the 'standard treatment' group, receiving a single PZQ treatment at baseline, or the 'intense treatment' group, receiving PZQ treatment at baseline and again at two, four, and six weeks after the initial dose, totalling four treatments with two-week intervals in the intense treatment group. Due to logistic reasons and school holidays, final sample collection had to be postponed from 8 weeks (as described in the study protocol (31)) to 10 weeks after baseline treatment (see S1 Fig).

### *Randomization and masking*

Eligible school-aged children were randomly assigned to the standard or intense treatment group, as described elsewhere (31). Participants as well as nurses and the study physician were not blinded to the treatment assignments, while laboratory technicians and investigators were blinded to the treatment assignments.

### *Outcomes*

The primary outcome was the difference in CR of a single versus four repeated PZQ treatments, based on KK in the intention-to-treat population. CR was defined as the proportion of children being *S. mansoni* egg-positive at baseline who became egg-negative 10 weeks after the first treatment. Secondary outcomes included the *S. mansoni* infection percentage positivity and intensity over time based on KK and POC-CCA, the CR based on POC-CCA, the IRR (defined as the percentage reduction in the median intensity, either expressed by eggs per gram of stool (EPG) or by visual score of the POC-CCA, of the positive individuals, 10 weeks after the first treatment, based on KK and POC-CCA), and safety of a single or multiple doses of PZQ.

### *Procedures*

Detailed descriptions of field and laboratory procedures are provided in the published study protocol (31). In brief, during the baseline survey, single urine and single stool samples were collected from each participating child. Urine samples were subjected to POC-CCA (batch #170522062; Rapid Medical Diagnostics, Pretoria, South Africa) using the semi-quantitative scoring method called 'G-scores' (32). With this POC-CCA batch, the provided quality control (QC) standard-series S0, S1, S2, and S3 resulted in a G1, G4, G8, and G10, respectively (see standard operating procedure (SOP), provided as an appendix in Casacuberta-Partal et al. (32)). To exclude the most abundant *S. haematobium* infections, urine filtration was performed on single

baseline urine samples. Stool samples were processed using the KK technique with triplicate 41.7 mg thick smears prepared from each sample, as described previously (31,33).

To assess treatment efficacy, additional urine and stool samples were collected from each participating child weekly and two-weekly, respectively, at eight time points over a period of 10 weeks. At each time point, all urine and stool samples were subjected to POC-CCA and KK, respectively, as described above.

### *Treatment and monitoring of adverse events*

At baseline, all included children were given PZQ (600 mg tablets; Biltricide, Bayer, Abidjan, Côte d'Ivoire), according to the calculated dose per kg of bodyweight (40 mg/kg, weight measured by a Seca 877 digital scale). Prior to treatment, breakfast was provided to each child. After sample collection, directly observed treatment was applied by the study physician and was accompanied with water and lunch, provided by the research team. Children allocated to the intense treatment group were re-treated with PZQ at 2, 4, and 6 weeks after the first treatment.

After treatment, children remained under medical supervision for at least 3 hours and adverse events were recorded. If needed, symptomatic treatment for adverse events was provided by the study physician. In case vomiting occurred within 1.5 hours, children were readministered a dose of PZQ. Twenty-four hours post-treatment, children were interviewed about the occurrence of adverse events. An adverse event was defined as any undesirable sign, symptom, or disease occurring to a participant during the study, whether or not related to PZQ treatment. Intensity of adverse events was graded by the study physician as mild, moderate, or severe, following guidelines by the European Medicine Agency.

### *Statistical analysis*

A detailed description of the sample size calculation is given elsewhere (31). In brief, to detect an increase in CR from 66% after a single PZQ treatment (12) to 99% after four repeated PZQ treatments with a two-sided 5% significance level and a power of 90%, a minimum sample size of 30 children per group was required (31, 34). To account for follow-up losses, expected due to the intense weekly follow-up, the sample size was increased to 100 children in each group, hence 200 children in total. Assuming a *S. mansoni* infection prevalence of approximately 25% based on KK (Taabo health and demographic surveillance site survey carried out in February 2016), at least 1,000 children needed to be screened in order to obtain a minimum of 200 KK-positive children in the Taabo region.

Data were double entered by two well-trained data entry clerks and managed using a REDCap electronic data capture tool hosted at Leiden University Medical Center (Leiden, the Netherlands), via Emory University (Atlanta, United States of America) (35,36). Descriptive statistics were performed using IBM Statistical Package for Social Sciences version 25 (SPSS Inc., Chicago, United States of America).

Infection intensity, as expressed by EPG, was calculated by multiplying the sum of egg counts from triplicate KK thick smears by a factor of 8. Intensity of infection was classified according to WHO guidelines into light (1–99 EPG), moderate (100–399 EPG), and heavy ( $\geq 400$  EPG) (5). POC-CCA G-scores were classified into negative (G1), trace (G2-3,


conservatively considered as negative in the analysis presented here), 1+ (G4-5), 2+ (G6-7), or 3+ (G8- 10) (10,22,32,37).

To determine the prevalence over time as well as CRs (based on KK and POC-CCA) and IRRs (based on KK), mixed effects models were employed to take into account the correlation between the different measurements from the same individual (38–40). For the prevalence, we used mixed effects logistic regression where prevalence was modeled as a function of time, treatment group and their interaction. In the case of KK, the time variable was taken as categorical, while for POC-CCA we modeled progression over time using natural cubic splines with four knots. For the KK-based IRR, we used a zero-inflated negative binomial mixed model where the logarithm of the mean egg counts is modeled as a function of time (using natural cubic splines), treatment group and their interaction. For POC-CCA, the IRRs could not be obtained from the mixed effects model, as the output (G-score) is not a continuous variable. Therefore, the IRR based on POC-CCA was calculated according to WHO guidelines  $(1 - (\text{arithmetic mean after treatment}/\text{arithmetic mean before treatment})) \times 100$  (41). In all models, the within subject correlation was modeled using a random intercepts term. The models used provide results under the missing at random assumption for the missing data which is valid in this study. All analyses were done in R (version 3.43) using the GLMMadaptive package. CR and IRR estimated from the model are given with their corresponding 95% pointwise confidence intervals (CIs). P-values <0.05 were considered to indicate statistical significance.

## RESULTS

Fig 1 shows the study flow. At baseline, 1,022 children aged 5–17 years were assessed for eligibility. Of these, 153 had a detectable *S. mansoni* infection and met the inclusion criteria. They were randomly assigned to one of the two study arms; 70 were assigned to the standard treatment group, and 83 were assigned to the intense treatment group. Regular randomization was performed instead of block randomization, and hence, the size of the two groups differed. At baseline, all 153 children (100%) received treatment. Three children (one in the standard treatment group and two in the intense treatment group) were lost to follow-up from week 6 onwards because they moved out of the study region during the follow-up period (see S1 Table). In the intense treatment group, compliance to each following treatment was unexpectedly high, from 100% in week 2 (second treatment) to 98% in week 6 (fourth and final treatment). All 153 children were included in the intention-to-treat analysis.

The demographic and parasitological baseline data for the participating children are summarized in Table 1. The median age and sex of children were balanced among the two groups. In both groups, most of the children had a light to moderate *S. mansoni* infection, while heavy infection intensities were observed in 18 (26%) children in the standard treatment group compared to 12 (14%) children in the intense treatment group. At pre-treatment, the median fecal egg count was 172 EPG and the median G-score in urine was 6 in the standard treatment group, and 128 EPG and G-score 7 in the intense treatment group, respectively.



**Figure 1.** Trial profile.

- a. Sample (urine and/or stool) not provided.  
 b. Intention-to-treat analysis.

*Prevalence over time*

Figure 2 illustrates the percentage of *S. mansoni* positives over time based on KK (Fig 2A) and on POC-CCA (Fig 2B). In the standard treatment group, the overall *S. mansoni* prevalence based on triplicate KK thick smears was decreased from 100% to 58% (95% CI 48–68%), measured 10 weeks after treatment. In the intense treatment group, who received a total of four doses of PZQ, the prevalence decreased to 14% (95% CI 8–23%), measured 10 weeks after the first treatment. Based on POC-CCA, measured at the final follow-up time point, 82% (95% CI 72–89%) and 64% (95% CI 54–74%) POC-CCA positives were observed in the standard and intense treatment group, respectively.

**Table 1. Baseline characteristics of the standard treatment group and the intense treatment group in a randomized trial.** The trial was conducted in late 2018 among school-aged children in south-central Côte d'Ivoire and compared single versus four repeated PZQ treatments against *S. mansoni*.


	Standard treatment group (1x PZQ) N=70	Intense treatment group (4x PZQ) N=83
Age, years	10.5 (9-12)	10.0 (9-12)
Weight, kg	32.2 (27.3-38.4)	32 (26.5-38.0)
Height, cm	137 (130-145)	140 (128-146)
Haemoglobin (g/dl)	11.3 (10.8-11.8)	11.3 (10.8-12.0)
Sex		
Boys	43 (61.4%)	51 (61.4%)
Girls	27 (38.6%)	32 (38.6%)
Village		
Ahouaty	35 (50.0%)	41 (49.4%)
N'Denou	27 (38.6%)	33 (39.8%)
Singrobo	8 (11.4%)	9 (10.8%)
Infection intensity		
Kato-Katz		
Light (1-99 EPG)	24 (34.3%)	35 (42.2%)
Moderate (110-399 EPG)	28 (40.0%)	36 (43.4%)
Heavy ( $\geq$ 400 EPG)	18 (25.7%)	12 (14.4%)
POC-CCA <sup>a</sup>		
1+	16 (22.9%)	22 (26.5%)
2+	38 (54.2%)	50 (60.2%)
3+	16 (22.9%)	11 (13.3%)

Data are median (IQR) or n (%). Abbreviations: EPG, eggs per gram of stool; IQR, interquartile range; POC-CCA, point-of-care circulating cathodic antigen.

<sup>a</sup> POC-CCA positive G-scores were classified into 1+ (G4-5), 2+ (G6-7) or 3+ (G8-10).

### Intensity of infection over time

The intensity of infection over time based on KK and POC-CCA is shown in Fig 3 (see also S2 Fig and S3 Fig). Based on the KK technique (Fig 3A and 3B), most of the remaining infections after the first treatment were of low intensity. In the standard treatment group, the proportion of low, moderate and, to a smaller extent, heavy intensity infections showed an increase 10 weeks after treatment. In the intense treatment group, a small proportion of infections of low intensity was observed at the final time point. Based on POC-CCA (Fig 3C and 3D), the overall prevalence did not change dramatically and the proportion of 3+ scores (indicating high infection level) remained similar over time in the standard treatment group as well as in the intense treatment group. The proportion of POC-CCA negatives (including traces) increased over time, particularly in the intense treatment group. In both groups, most children remained POC-CCA positive at the final time point. A positive correlation was observed between fecal egg counts and POC-CCA visual scores before treatment (Spearman's  $\rho = 0.44$ ,  $P < 0.01$ ) (S4 Fig).



**Figure 2.** Prevalence over time (with corresponding pointwise 95% confidence intervals) estimated from the mixed effects logistic regression model. Data pertain to (a) triplicate Kato-Katz (KK) thick smears from a single stool sample and (b) single point-of-care circulating cathodic antigen (POC-CCA) urine test in the standard treatment group (single dose of PZQ, solid line) and the intense treatment group (four doses of PZQ at W0, W2, W4, and W6, dashed line).

### Cure rate

In the standard treatment group, CR based on triplicate KK thick smears was 42% (95% CI 31–53%) (Table 2; see also S2 Table). A significantly higher CR (86%, 95% CI 75–92%) was observed in the intense treatment group, ( $P < 0.001$ ; primary outcome, both CRs measured 10 weeks after first treatment). When using the same time interval post-treatment to compare CRs between the two groups, i.e., four weeks after the first treatment for the standard treatment group and four weeks after the fourth treatment for the intense treatment group, the observed CR in the standard treatment group was 68% (95% CI 57–78%) compared to 86% (95% CI 75–92%) in the intense treatment group ( $P < 0.01$ ).

POC-CCA-based CRs were much lower compared to CRs based on the KK technique; only 18% (95% CI 11–27%) in the standard treatment group and 36% (95% CI 26–46%) in the intense treatment group ( $P < 0.01$ ). Using the 4-week post-treatment time points, CRs were similar in both groups; 31% (95% CI 23–40%) in the standard treatment group and 36% (95% CI 26–46%) in the intense treatment group ( $P = 0.23$ ).


### Intensity reduction rate

Based on the KK technique, the IRR in the standard treatment group was 72% (95% CI 55–83%), compared to 95% (95% CI 85–98%) in the intense treatment group ( $P < 0.01$ ). When using the same time interval post-treatment to compare IRRs between the two groups (4 weeks), the observed IRR in the standard treatment group was 83% (95% CI 69–91%) versus 95% (95% CI 85–98%) in the intense treatment group ( $P < 0.01$ ). The decrease in the mean POC-CCA G-score was larger in the intense treatment group compared to the standard treatment group, resulting

in an IRR of 27% and 9%, respectively (measured 10 weeks after first treatment). When using the same time interval post-treatment for the standard treatment group, the IRR was 20%.

*Safety of PZQ*

Observed and reported (within 3 hours) adverse events are summarized in Table 3, stratified by treatment group and follow-up time point. After the first treatment, stomach ache was the most common adverse event (overall 38%), followed by headache (overall 5%) and vomiting (overall 3%). Most of the adverse events were mild and all of them resolved 24 hours after treatment. Adverse events decreased with subsequent treatments in the intense treatment group.



**Figure 3. Intensity of infection.** Data are based on triplicate Kato-Katz (KK) thick smears from a single stool sample (a, b) and single point-of-care circulating cathodic antigen (POC-CCA) urine test (c, d) in the standard treatment group (single dose of PZQ) and the intense treatment group (four doses of PZQ at W0, W2, W4, and W6).

**Table 2. Cure rate (CR) and intensity reduction rate (IRR) of a single (standard treatment group) and four (intense treatment group) repeated PZQ treatments in school-aged children infected with *S. mansoni*.** Data are based on triplicate Kato-Katz thick smears from a single stool sample and single point-of-care circulating cathodic antigen (POC-CCA) urine test.

	Standard treatment group (1x PZQ) N=70	Intense treatment group (4x PZQ) N=83
<b>Kato-Katz</b>		
Infected children before treatment	70	83
Cured children 10 weeks after first treatment	28	69
CR <sup>a,b</sup>	41.6% (95% CI 31.1-52.9)	86.0% (95% CI 75.4-92.4)
Cured children 4 weeks post-treatment <sup>c</sup>	47	69
CR <sup>b</sup>	68.2% (95% CI 57.1-77.6)	86.0% (95% CI 75.4-92.4)
Median EPG <sup>d</sup>		
Before treatment	172	128
10 weeks after first treatment	64	8
4 weeks post-treatment <sup>c</sup>	36	8
Arithmetic mean EPG		
Before treatment	298.2	242.7
10 weeks after first treatment	97.7	3.2
IRR <sup>e</sup>	72.3% (95% CI 54.6-83.1)	95.1% (95% CI 85.1-98.4)
4 weeks post-treatment <sup>c</sup>	45.8	3.2
IRR <sup>e</sup>	83.3% (95% CI 68.9-91.2)	95.1% (95% CI 85.1-98.4)
<b>POC-CCA</b>		
Infected children before treatment	70	83
Cured children 10 weeks after first treatment	15	29
CR <sup>b</sup>	17.9% (95% CI 11.3-27.2)	35.7% (95% CI 26.4-46.1)
Cured children 4 weeks post-treatment <sup>c</sup>	26	29
CR <sup>b</sup>	31.2% (95% CI 23.4-40.2)	35.7% (95% CI 26.4-46.1)
Median G-score <sup>d</sup>		
Before treatment	6	7
10 weeks after first treatment	7	6
4 weeks post-treatment <sup>c</sup>	6	6
Arithmetic mean G-score		
Before treatment	6.4	6.3
10 weeks after baseline treatment	5.8	4.6
IRR <sup>f</sup>	9.3%	27.0%
4 weeks post-treatment <sup>c</sup>	5.1	4.6
IRR <sup>f</sup>	20.3%	27.0%

Abbreviations: CR, cure rate; EPG, eggs per gram of stool; IRR, intensity reduction rate; POC-CCA, point-of-care circulating cathodic antigen test

<sup>a</sup> Primary outcome

<sup>b</sup> CR as calculated from the model

<sup>c</sup> Measured four weeks after first treatment for the standard treatment group, and four weeks after the fourth treatment for the intense treatment group

<sup>d</sup> Median of the positives

<sup>e</sup> IRR based on the reduction in mean EPG as calculated from the model

<sup>f</sup> IRR based on the reduction in mean POC-CCA G-score as calculated manually

**Table 3. Main type of adverse events observed and reported 3 hours after PZQ administration in *S. mansoni*-infected children in the standard treatment group and the intense treatment group.**

	Standard treatment group		Intense treatment group							
	First treatment W0		First treatment W0		Second treatment W2		Third treatment W4		Fourth treatment W6	
	N=70		N=83		N=82		N=82		N=78	
<b>Adverse events</b>										
Stomach ache	25	36%	33	40%	25	30%	22	27%	10	13%
Headache	3	4%	5	6%	14	17%	4	5%	2	3%
Vomiting	3	4%	2	2%	2	2%	4	5%	2	3%
Dizziness	2	3%	2	2%	3	4%	9	11%	6	8%
Diarrhoea	2	3%	1	1%	0		0		0	
Nausea	0		0		0		1	1%	1	1%

## DISCUSSION

Based on stool microscopy, we observed a significantly higher CR after four closely spaced PZQ treatments compared to a single dose, measured 10 weeks after the first treatment, without any difference in the frequency and severity of adverse events. Employing the POC-CCA test, the observed CRs were considerably lower compared to KK, even after four repeated treatments, indicating that worms are still present and that PZQ might be less efficacious than previously published.

Our aim of administering PZQ four times at 2-week intervals was to achieve a high CR, as this approach not only targets adult schistosomes, but also the immature forms, which were not yet drug-susceptible during the first treatment (12,29,42). Indeed, 10 weeks after the baseline survey, four repeated treatments resulted in a significantly higher CR than a single treatment based on the KK technique, but failed to cure all infections. The primary outcome according to the study protocol, i.e., the difference in CR of a single versus four repeated PZQ treatments, was calculated by comparing the prevalence of infection at baseline and 10 weeks after the first treatment (31). This implied that the time interval after treatment was not the same for both groups; 10 weeks after the single treatment in the standard treatment group (allowing for a 10-week period of possible worm maturation, worm recovery, as well as renewed parasite exposure and re-infection) versus four weeks after the fourth treatment in the intense treatment group. To render the comparison between the groups more representative, CRs were also determined using the same time interval for both groups, i.e., for the standard treatment group taking four weeks after the first treatment as the final time point. While the CR in the standard treatment group was significantly higher four weeks after treatment compared to the CR obtained 10 weeks after treatment, there was no significant difference in the CRs between the standard treatment group and the intense treatment group four weeks after the last treatment, measured with both KK and POC-CCA. Hence, following this evaluation approach, there is no indication that four repeated PZQ treatments outperform a single treatment in curing schistosomiasis.

Moreover, although four repeated PZQ treatments resulted in a statistically significantly higher CR when utilizing the KK technique compared to POC-CCA, the estimated

CR was considerably lower than what we had expected (31), and the proportion of KK-positives increased again from 1% before the fourth treatment to 14% four weeks after the fourth treatment. This might indicate continued parasite exposure, ongoing re-infection, and worm maturation after treatment over the course of the study, not excluding possible PZQ resistance.

Compliance to treatment was very high at each treatment, most likely due to the relatively mild and short-lived adverse events in combination with the commitment of the field and laboratory team, and enthusiastic participation of children. At each treatment time point, directly observed treatment was applied by the study physician. We therefore conclude that the observed increase in proportion of KK-positives at the final time point in the intense treatment group cannot be explained by the fact that some children might not have taken the (repeatedly) administered drugs, but points to parasite survival in the host or rapid reinfection.

To more accurately assess the CR, the POC-CCA test was employed in addition to KK. CRs based on POC-CCA were significantly lower in both groups compared to CRs based on the KK technique. Even though the number of POC-CCA negatives increased after four treatments, still more than half of the participants remained positive (traces conservatively considered as negative), indicating that active *Schistosoma* infections were still present in our cohort or new infections occurred within short periods.

Previous studies have demonstrated false positive POC-CCA results in people with urinary tract infections (43) as well as potentially in pregnant women (44) and new born babies. In our study, no urinary tract infections were noted, two female participants were excluded because of possible pregnancy, and only children aged 5 years and above were included. To further minimize the inclusion of false positives, traces were considered as negative in our analysis. Recent studies have shown that prevalence estimates of *S. mansoni* below 20% according to the KK technique might correspond to POC-CCA prevalence estimates that are 3- to 4-fold higher (18,5). Furthermore, studies applying latent class analysis to determine the performance of diagnostic assays have shown that the POC-CCA test has a considerably greater sensitivity and a comparable specificity than the KK technique, especially when traces are considered negative (20,46). In contrast, other studies have shown that POC-CCA might be of limited use to diagnose *S. mansoni* infection, especially in low endemic areas (47). More accurate diagnostic methods, such as PCR (48,49) or the upconverting phosphor lateral flow (UCP-LF) assay detecting circulating anodic antigen (50), both being well established laboratory-based assays, could be used to determine prevalence more accurately.

It is important to note that the two diagnostic methods employed in our study detect different *Schistosoma* life-cycle stages, namely eggs in case of KK thick smears examined under a microscope and antigens derived from adult worms in case of the POC-CCA urine test. Finding a high proportion of individuals positive by POC-CCA after treatment, while no eggs are detected by KK, indicates that the infection is not fully cured. Mature worms could have been affected by PZQ but not killed, resulting in the (temporary) reduction or cessation of fecal egg excretion (13), while still excreting CCA detectable by POC-CCA. Furthermore, individuals can harbor living (single sex) worms with only sporadically excreting eggs in stool or with no detectable eggs at all (51–54). CCA might also originate from new infections or immature worms (55) or perhaps from dead worms that were killed by PZQ. Lastly, PZQ treatment could have resulted in a reduction of fecundity, indicating that egg-based diagnostic methods will

overestimate the reduction in worm burden (56,57). However, even with the presence of low worm numbers, which excrete relatively few eggs, there is a continued risk of pathology (58,59), as eggs could retain in the host tissue, where they induce inflammatory responses resulting in 'subtle morbidity' (60).

Little is known about the transmission of schistosomes in the study setting of south-central Côte d'Ivoire; transmission is suspected to be ongoing, given the number of observed cases and the frequent surface water contact of the inhabitants with the man-made Lake Taabo (27,30). This trial focused on simply measuring the efficacy of PZQ and did not include sanitation and behavioral interventions, which in this specific setting would have had an additional impact on the number and intensity of *Schistosoma* infections. Moreover, since this study focused on a subset of school-aged children, other children in the same age range, as well as preschool-aged children or adolescents/adults from the community would still serve as a reservoir of infection and therefore contribute to ongoing transmission.

The CR and IRR as determined by the KK technique were higher after four treatments compared to a single treatment, both at four and 10 weeks after treatment. This observation suggests that repeated treatment has an added value on reducing the number of infections and *Schistosoma*-related infection intensity and thus morbidity in areas where people are likely infected with different developmental stages of the parasite and rapid re-infection is obvious. However, since microscopy lacks sensitivity, especially in infections of low intensity and posttreatment settings, not being able to detect eggs does not necessarily mean that the infection is cured and that all worms have been killed. In contrast to the high IRR based on the KK technique, only a minor reduction in POC-CCA-based infection intensity was observed, which did not increase significantly after four repeated PZQ treatments. This contradicts previous studies that indicated a decrease in POC-CCA intensity score rapidly after treatment (20,47,61). More accurate diagnostic methods, such as the UCP-LF CAA test or quantitative PCR could be applied to more accurately determine the reduction in intensity.

Previous studies indicate that the frequency and severity of adverse events is related to *Schistosoma* infection intensity, with more events reported in infections with a heavy intensity (62,63). Over the course of the trial, mostly mild and short-lived adverse events were observed, which presumably can be attributed to the relatively low intensity of infection in our study population. Overall, repeated PZQ treatment was well tolerated, indicating that repeated PZQ treatment can be considered as safe. Repeated PZQ treatment might help to enhance the control of schistosomiasis. This should not preclude the notion that treatment, whether single or repeated, should always be combined with other control measures, such as behavior change, sanitation, safe water, and snail control interventions in order to bolster the effect of PZQ and to move toward interruption of transmission.

## CONCLUSION

Based on stool microscopy using the KK technique, four repeated doses of 40 mg/kg PZQ at 2-week intervals resulted in a CR against *S. mansoni* infection of 86%, as determined 10 weeks after the initial treatment. When using the more sensitive POC-CCA test, the observed CR was significantly lower (27%), indicating that PZQ might not be as efficacious as previously reported.

The same trend is shown when efficacy is expressed as IRR, which highlights the relevance of accurate diagnostic methods in monitoring treatment efficacy as well as other control approaches (e.g. vaccine development). This study signifies that the development and field implementation of reliable and more accurate diagnostic tools are essential to systematically map transmission intensity and measure efficacy of control strategies, ultimately providing rational guidance on the path toward elimination of schistosomiasis.

### **Acknowledgments**

We would like to thank all children for providing stool and urine samples and for their enthusiastic participation. We are grateful to the parents and guardians of children and the communities for allowing us to conduct this trial as well as to all the technicians, nurses, volunteers and drivers who assisted us during the field and laboratory work. We also thank the Data Safety Monitoring Board (DSMB) members A.L. Bustinduy (Chair), R.G.M. Bredius, and K. Kouakou for their contribution and oversight. We thank D. Kornelis for her support with the statistical analysis. Special thanks are addressed to the directors and staff of Centre Suisse de Recherches Scientifiques en Côte d'Ivoire and the 'Programme National de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive' for administrative support.

### **Author Contributions**

Conceptualization: Pytsje T. Hoekstra, Lisette van Lieshout, Meta Roestenberg, Stefanie Knopp, Jürg Utzinger, Jean T. Coulibaly, Govert J. van Dam.

Data curation: Pytsje T. Hoekstra, Miriam Casacuberta-Partal, Roula Tsonaka.

Formal analysis: Pytsje T. Hoekstra, Roula Tsonaka.

Funding acquisition: Govert J. van Dam.

Investigation: Pytsje T. Hoekstra, Miriam Casacuberta-Partal, Rufin K. Assaré, Kigbafori D. Silué, Yves K. N'Gbesso, Jean T. Coulibaly, Govert J. van Dam.

Methodology: Pytsje T. Hoekstra, Meta Roestenberg, Stefanie Knopp, Jürg Utzinger, Jean T. Coulibaly, Govert J. van Dam.

Project administration: Pytsje T. Hoekstra, Miriam Casacuberta-Partal, Rufin K. Assaré, Kigbafori D. Silué, Jean T. Coulibaly.

Resources: Pytsje T. Hoekstra, Miriam Casacuberta-Partal, Rufin K. Assaré, Kigbafori D. Silué, Aboulaye Meité, Eliézer K. N'Goran, Jean T. Coulibaly, Govert J. van Dam.

Software: Roula Tsonaka.

Supervision: Lisette van Lieshout, Abena S. Amoah, Meta Roestenberg, Jean T. Coulibaly, Govert J. van Dam.

Validation: Pytsje T. Hoekstra, Miriam Casacuberta-Partal, Govert J. van Dam.

Visualization: Pytsje T. Hoekstra.

Writing – original draft: Pytsje T. Hoekstra.

Writing – review & editing: Pytsje T. Hoekstra, Miriam Casacuberta-Partal, Lisette van Lieshout, Paul L. A. M. Corstjens, Abena S. Amoah, Meta Roestenberg, Stefanie Knopp, Jürg Utzinger, Govert J. van Dam.

### **Author details**

1. Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands;
2. Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands;
3. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands;
4. Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire;
5. Unité de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire;
6. Swiss Tropical and Public Health Institute, Basel, Switzerland;
7. University of Basel, Basel, Switzerland;
8. Programme National de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive, Ministère de la Santé et de l'Hygiène Publique, Abidjan, Côte d'Ivoire;
9. Département d'Agboville, Centre de Santé Urbain d'Azaguié, Azaguié, Côte d'Ivoire;

10. Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom;
11. Malawi Epidemiology and Intervention Research Unit, Chilumba, Karonge District, Malawi;
12. Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

### Data Availability Statement

All relevant data are available within the manuscript and its supporting information file.

### Funding

This work received financial support from the Prof. Dr. Flu Foundation, based in the Netherlands and the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), which is funded at The Task Force for Global Health, primarily by the Bill & Melinda Gates Foundation, by the United States Agency for International Development through its Neglected Tropical Disease Program, and with UK aid from the British people. The funders had no role in the design of the study, data collection, analysis and interpretation, or preparation of the manuscript.

## REFERENCES

1. WHO. Schistosomiasis 2019 [Available from: <https://www.who.int/en/news-room/fact-sheets/detail/schistosomiasis>].
2. Hotez PJ, Alvarado M, Basáñez MG, Bolliger I, Bourne R, Boussinesq M, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. *PLoS Negl Trop Dis*. 2014; 8(7):e2865.
3. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. *Lancet*. 2014; 383(9936):2253–64.
4. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. *Nat Rev Dis Primers*. 2018; 4(1):13.
5. WHO. Schistosomiasis: progress report 2001–2011 and strategic plan 2012–2020 Geneva: World Health Organization; 2013.
6. French MD, Evans D, Fleming FM, Secor WE, Biritwum NK, Brooker SJ, et al. Schistosomiasis in Africa: improving strategies for long-term and sustainable morbidity control. *PLoS Negl Trop Dis*. 2018; 12(6):e0006484.
7. Andrade G, Bertsch DJ, Gazzinelli A, King CH. Decline in infection-related morbidities following drug-mediated reductions in the intensity of *Schistosoma* infection: a systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2017; 11(2):e0005372.
8. WHO. Helminth control in school age children: a guide for managers of control programmes - 2nd ed. Geneva: World Health Organization; 2011.
9. WHO. Preventive chemotherapy in human helminthiasis: coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization; 2006.
10. Knopp S, Becker SL, Ingram KJ, Keiser J, Utzinger J. Diagnosis and treatment of schistosomiasis in children in the era of intensified control. *Expert Rev Anti Infect Ther*. 2013; 11(11):1237–58.
11. Keiser J, N'Gouessan NA, Adoubryn KD, Silué KD, Vounatsou P, Hatz C, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against *Schistosoma haematobium*: randomized, exploratory open-label trial. *Clin Infect Dis*. 2010; 50(9):1205–13.
12. King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. *PLoS Negl Trop Dis*. 2011; 5(9):e1321.
13. Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. *Parasit Vectors*. 2017; 10(1):47.
14. Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis: a meta-analysis of comparative and non-comparative clinical trials. *PLoS Negl Trop Dis*. 2014; 8(11):e3286.
15. Munisi DZ, Buza J, Mpolya EA, Angelo T, Kinung'hi SM. The efficacy of single-dose versus double-dose praziquantel treatments on *Schistosoma mansoni* infections: its implication on undernutrition and anaemia among primary schoolchildren in two on-shore communities, northwestern Tanzania. *Biomed Res Int*. 2017; 2017:7035025.
16. Nalugwa A, Nuwaha F, Tukahebwa EM, Olsen A. Single versus double dose praziquantel comparison on efficacy and *Schistosoma mansoni* re-infection in preschool-age children in Uganda: a randomized controlled trial. *PLoS Negl Trop Dis*. 2015; 9(5):e0003796.
17. Knopp S, Ame SM, Hattendorf J, Ali SM, Khamis IS, Bakar F, et al. Urogenital schistosomiasis elimination in Zanzibar: accuracy of urine filtration and haematuria

- reagent strips for diagnosing light intensity *Schistosoma haematobium* infections. *Parasit Vectors*. 2018; 11(1):552.
18. Bärenbold O, Garba A, Colley DG, Fleming FM, Haggag AA, Ramzy RMR, et al. Translating preventive chemotherapy prevalence thresholds for *Schistosoma mansoni* from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test. *PLoS Negl Trop Dis*. 2018; 12(12):e0006941.
  19. Lamberton PH, Kabatereine NB, Oguttu DW, Fenwick A, Webster JP. Sensitivity and specificity of multiple Kato-Katz thick smears and a circulating cathodic antigen test for *Schistosoma mansoni* diagnosis pre- and post-repeated-praziquantel treatment. *PLoS Negl Trop Dis*. 2014; 8(9):e3139.
  20. Mwinzi PN, Kittur N, Ochola E, Cooper PJ, Campbell CH Jr., King CH, et al. Additional evaluation of the point-of-contact circulating cathodic antigen assay for *Schistosoma mansoni* infection. *Frontiers in public health*. 2015; 3:48.
  21. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. *Clin Microbiol Infect*. 2015; 21(6):529–42.
  22. Colley DG, Binder S, Campbell C, King CH, Tchuem Tchuente LA, N’Goran EK, et al. A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of *Schistosoma mansoni*. *Am J Trop Med Hyg*. 2013; 88(3):426–32.
  23. WHO. Report of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases. Geneva: World Health Organization, 2015.
  24. Wilson RA, van Dam GJ, Kariuki TM, Farah IO, Deelder AM, Coulson PS. The detection limits for estimates of infection intensity in schistosomiasis *mansoni* established by a study in non-human primates. *Int J Parasitol*. 2006; 36(12):1241–4.
  25. Koukounari A, Donnelly CA, Moustaki I, Tukahebwa EM, Kabatereine NB, Wilson S, et al. A latent Markov modelling approach to the evaluation of circulating cathodic antigen strips for schistosomiasis diagnosis pre- and post-praziquantel treatment in Uganda. *PLoS Comput Biol*. 2013; 9(12):e1003402.
  26. Botros S, Pica-Mattoccia L, William S, El-Lakkani N, Cioli D. Effect of praziquantel on the immature stages of *Schistosoma haematobium*. *Int J Parasitol*. 2005; 35(13):1453–7.
  27. N’Goran EK, Utzinger J, N’Guessan AN, Müller I, Zambé K, Lohourignon KL, et al. Reinfection with *Schistosoma haematobium* following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d’Ivoire. *Trop Med Int Health*. 2001; 6(10):817–25.
  28. Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC, Roberts SA, Atuhaire A, van Dam GJ, et al. Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. *MBio*. 2016; 7(4).
  29. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. *Schistosoma mansoni*: chemotherapy of infections of different ages. *Exp Parasitol*. 1986; 61(3):294–303.
  30. Koné S, Baikoro N, N’Guessan Y, Jaeger FN, Silué KD, Fürst T, et al. Health & Demographic Surveillance System Profile: The Taabo health and demographic surveillance system, Côte d’Ivoire. *Int J Epidemiol*. 2015; 44(1):87–97.
  31. Hoekstra PT, Casacuberta P, Amoah AS, van Lieshout L, Corstjens P, Tsonaka S, et al. Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST)—single versus multiple praziquantel treatments in school-aged children in Côte d’Ivoire: a study protocol for an open-label, randomised controlled trial. *BMC Infect Dis*. 2018; 18(1):662.
  32. Casacuberta-Partal M, Hoekstra PT, Cornelis D, van Lieshout L, van Dam GJ. An innovative and userfriendly scoring system for standardised quantitative interpretation of the urine-based point-of-care strip test (POC-CCA) for the diagnosis of intestinal schistosomiasis: a proof-of-concept study. *Acta Trop*. 2019; 199:105150.
  33. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in schistosomiasis *mansoni*. *Rev Inst Med Trop Sao Paulo*. 1972; 14:397–400.
  34. Machin D, Campbell MJ, Tan SB, Tan SH. Comparing two independent groups for binary data. *Sample Size Tables for Clinical Studies*: Wiley-Blackwell; 2009. p. 30–41.
  35. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009; 42(2):377–81.
  36. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform*. 2019; 95:103208.
  37. Coulibaly JT, N’Gbesso YK, Knopp S, N’Guessan NA, Silué KD, van Dam GJ, et al. Accuracy of urine circulating cathodic antigen test for the diagnosis of *Schistosoma mansoni* in preschool-aged children before and after treatment. *PLoS Negl Trop Dis*. 2013; 7(3):e2109.
  38. Walker M, Churcher TS, Basáñez MG. Models for measuring anthelmintic drug efficacy for parasitologists. *Trends Parasitol*. 2014; 30(11):528–37.
  39. Walker M, Mabud TS, Olliaro PL, Coulibaly JT, King CH, Raso G, et al. New approaches to measuring anthelmintic drug efficacy: parasitological responses of childhood

- schistosome infections to treatment with praziquantel. *Parasit Vectors*. 2016; 9:41.
40. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, et al. Toward measuring *Schistosoma* response to praziquantel treatment with appropriate descriptors of egg excretion. *PLoS Negl Trop Dis*. 2015; 9(6):e0003821.
  41. WHO. Assessing the efficacy of anthelmintic drugs against schistosomiasis and soil-transmitted helminthiasis. Geneva: World Health Organization; 2013.
  42. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. *Curr Opin Infect Dis*. 2008; 21(6):659–67.
  43. RMD. Technical Brochure—Rapid test for qualitative detection of: Bilharzia (Schistosomiasis). [http://www.rapid-diagnostics.com/updates\\_15\\_09\\_2019/RMD\\_Pamphlet\\_13\\_12\\_2018\\_Colourweb.pdf](http://www.rapid-diagnostics.com/updates_15_09_2019/RMD_Pamphlet_13_12_2018_Colourweb.pdf)2018.
  44. Greter H, Krauth SJ, Ngandolo BN, Alfaroukh IO, Zinsstag J, Utzinger J. Validation of a point-of-care circulating cathodic antigen urine cassette test for *Schistosoma mansoni* diagnosis in the Sahel, and potential cross-reaction in pregnancy. *Am J Trop Med Hyg*. 2016; 94(2):361–4.
  45. Kittur N, Castleman JD, Campbell CH Jr., King CH, Colley DG. Comparison of *Schistosoma mansoni* prevalence and intensity of infection, as determined by the circulating cathodic antigen urine assay or by the Kato-Katz fecal assay: a systematic review. *Am J Trop Med Hyg*. 2016; 94(3):605–10.
  46. Clements MN, Corstjens P, Binder S, Campbell CH Jr., de Dood CJ, Fenwick A, et al. Latent class analysis to evaluate performance of point-of-care CCA for low-intensity *Schistosoma mansoni* infections in Burundi. *Parasit Vectors*. 2018; 11(1):111.
  47. Sousa MS, van Dam GJ, Pinheiro MCC, de Dood CJ, Peralta JM, Peralta RHS, et al. Performance of an ultra-sensitive assay targeting the circulating anodic antigen (CAA) for detection of *Schistosoma mansoni* infection in a low endemic area in Brazil. *Front Immunol*. 2019; 10(682).
  48. Lodh N, Mwansa JC, Mutengo MM, Shiff CJ. Diagnosis of *Schistosoma mansoni* without the stool: comparison of three diagnostic tests to detect *Schistosoma* [corrected] *mansoni* infection from filtered urine in Zambia. *Am J Trop Med Hyg*. 2013; 89(1):46–50.
  49. Meurs L, Brien E, Mbow M, Ochola EA, Mboup S, Karanja DM, et al. Is PCR the next reference standard for the diagnosis of *Schistosoma* in stool? A comparison with microscopy in Senegal and Kenya. *PLoS Negl Trop Dis*. 2015; 9(7):e0003959.
  50. Corstjens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Kariuki TM, et al. Tools for diagnosis, monitoring and screening of *Schistosoma* infections utilizing lateral-flow based assays and upconverting phosphor labels. *Parasitology*. 2014; 141(14):1841–55.
  51. Utzinger J, Booth M, N'Goran EK, Müller I, Tanner M, Lengeler C. Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of *Schistosoma mansoni* before and after treatment with praziquantel. *Parasitology*. 2001; 122(05):537–44.
  52. Engels D, Sinzinkayo E, Gryseels B. Day-to-day egg count fluctuation in *Schistosoma mansoni* infection and its operational implications. *Am J Trop Med Hyg*. 1996; 54(4):319–24.
  53. Colley DG, Andros TS, Campbell CH Jr. Schistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs? *Infect Dis Poverty*. 2017; 6(1):63.
  54. Haggag AA, Rabiee A, Abd Elaziz KM, Campbell CH, Colley DG, Ramzy RMR. Thirty-day daily comparisons of Kato-Katz and CCA assays of 45 Egyptian children in areas with very low prevalence of *Schistosoma mansoni*. *Am J Trop Med Hyg*. 2019; 100(3):578–83.
  55. van Dam GJ, Bogtsh BJ, van Zeyl RJ, Rotmans JP, Deelder AM. *Schistosoma mansoni*: in vitro and in vivo excretion of CAA and CCA by developing schistosomula and adult worms. *J Parasitol*. 1996; 82(4):557–64.
  56. Lamberton PHL, Faust CL, Webster JP. Praziquantel decreases fecundity in *Schistosoma mansoni* adult worms that survive treatment: evidence from a laboratory life-history trade-offs selection study. *Infect Dis Poverty*. 2017; 6(1):110.
  57. Wilson S, Jones FM, van Dam GJ, Corstjens PL, Riveau G, Fitzsimmons CM, et al. Human *Schistosoma haematobium* antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigens. *J Infect Dis*. 2014; 210(12):2009–16.
  58. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet*. 2005; 365(9470):1561–9.
  59. King CH. It's time to dispel the myth of "asymptomatic" schistosomiasis. *PLoS Negl Trop Dis*. 2015; 9(2):e0003504.
  60. Colley DG, Secor WE. Immunology of human schistosomiasis. *Parasite Immunol*. 2014; 36(8):347–57.
  61. Kildemoes AO, Vennervald BJ, Tukahebwa EM, Kabatereine NB, Magnussen P, de Dood CJ, et al. Rapid clearance of *Schistosoma mansoni* circulating cathodic antigen after treatment shown by urine strip tests in a Ugandan fishing community—relevance for monitoring treatment efficacy and re-infection. *PLoS Negl Trop Dis*. 2017; 11(11):e0006054.
  62. Raso G, N'Goran EK, Toty A, Luginbühl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side


- effects of praziquantel against *Schistosoma mansoni* in a community of western Côte d'Ivoire. *Trans R Soc Trop Med Hyg.* 2004; 98(1):18–27..
63. Olds GR, King C, Hewlett J, Olveda R, Wu G, Ouma J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. *J Infect Dis.* 1999; 179(4):996–1003.

## SUPPLEMENTARY MATERIALS


## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>	1a	Identification as a randomised trial in the title	Title
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	Abstract
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	Introduction
	2b	Specific objectives or hypotheses	Introduction, paragraph 4
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Methods, paragraph 2-4
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	Methods, paragraph 3
	4b	Settings and locations where the data were collected	Methods, paragraph 2
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Methods, paragraph 4, 9, 10
	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	Methods, paragraph 6
Outcomes	6b	Any changes to trial outcomes after the trial commenced, with reasons	Methods, paragraph 4
	7a	How sample size was determined	Methods, paragraph 11
Sample size	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	Methods, paragraph 5
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	Methods, paragraph 5
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Methods, paragraph 5
	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Methods, paragraph 5
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Methods, paragraph 5
	11b	If relevant, description of the similarity of interventions	
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	Methods, paragraph 14
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	Methods, paragraph 14
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Results, paragraph 1
	13b	For each group, losses and exclusions after randomisation, together with reasons	Results, paragraph 1 and S1 Table
Recruitment	14a	Dates defining the periods of recruitment and follow-up	Methods, paragraph 3
	14b	Why the trial ended or was stopped	NA
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Results, paragraph 2 and Table 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Results, paragraph 1 and Figure 1
	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Results, paragraph 3-6 and Table 2
Outcomes and estimation	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Table 2
	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	NA
Ancillary analyses	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	Results, paragraph 7 and Table 3
<b>Harms</b>			
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	Discussion, paragraph 4, 5
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Discussion, paragraph 1, 2, 7 and Conclusion
	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Discussion, paragraph 7 and Conclusion
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	Abstract and Methods, paragraph 1 Published ( <a href="#">see</a> <a href="https://www.ncbi.nlm.nih.gov/pubmed/30547750">https://www.ncbi.nlm.nih.gov/pubmed/30547750</a> )
Protocol	24	Where the full trial protocol can be accessed, if available	<a href="https://www.ncbi.nlm.nih.gov/pubmed/30547750">https://www.ncbi.nlm.nih.gov/pubmed/30547750</a>
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	End of manuscript


\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).




S1 Figure. Schematic representation of follow-up, treatment and sampling procedures in the standard and intense treatment group. Adapted from the published study protocol.



S2 Figure. Intensity of infection of *KK*-positives over time based on triplicate thick smears from a single stool sample in the standard treatment group (single PZQ treatment) (a) and the intense treatment group (four repeated PZQ treatments at W0, W2, W4, and W6) (b).



S3 Figure. Individual intensity of infection over time based on triplicate Kato-Katz (KK) thick smears from a single stool sample (a, b) and single point-of-care circulating cathodic antigen (POC-CCA) urine test using visual scores (c, d) or G-scores (e, f) in the standard treatment group (single PZQ treatment) and the intense treatment group (four repeated PZQ treatments at W0, W2, W4, and W6).



S4 Figure. Correlation between EPG (based on KK) and G-scores (based on POC-CCA) before treatment.

**S1 Table. Detailed overview of missing samples and drop-outs during follow-up in the standard treatment group and the intense treatment group.**

	Standard treatment group (1x PZQ) N=70			Intense treatment group (4x PZQ) N=83		
	Total	Missing	Participant ID	Total	Missing	Participant ID
<b>W0</b>						
Received PZQ treatment	N=70	N=0		N=83	N=0	
Provided stool sample	N=70	N=0		N=83	N=0	
Provided urine sample	N=70	N=0		N=83	N=0	
<b>W1</b>						
Provided urine sample	N=70	N=0		N=83	N=0	
<b>W2</b>						
Received PZQ treatment	NA	NA		N=82	N=1	2023
Provided stool sample	N=68	N=2	1155 2453	N=82	N=1	2023
Provided urine sample	N=68	N=2	1155 2453	N=82	N=1	
<b>W3</b>						
Provided urine sample	N=70	N=0		N=83	N=0	
<b>W4</b>						
Received PZQ treatment	NA	NA		N=82	N=1	2457
Provided stool sample	N=69	N=1	1105	N=83	N=0	
Provided urine sample	N=70	N=0		N=83	N=0	
<b>W5</b>						
Provided urine sample	N=69	N=1	1535	N=83	N=0	
<b>W6</b>						
Received PZQ treatment						2050 <sup>a</sup> 2149 2260 2282 2457 <sup>a</sup> 1425 2050 <sup>a</sup>
	NA	NA		N=78	N=5	2149 2282 2457 <sup>a</sup> 2050 <sup>a</sup>
Provided stool sample	N=68	N=2	1105 <sup>a</sup> 2449	N=77	N=6	2149 2282 2371 2457 <sup>a</sup> 2050 <sup>a</sup>
Provided urine sample	N=69	N=1	1105 <sup>a</sup>	N=79	N=4	2149 2282 2457 <sup>a</sup>
<b>W7</b>						
Provided urine sample			1105 <sup>a</sup> 1416 1549 2336	N=77	N=6	1243 2050 <sup>a</sup> 2146 2149 2282 2457 <sup>a</sup>
<b>W10</b>						
Provided stool sample	N=67	N=3	1034 1105 <sup>a</sup> 1155	N=80	N=3	1512 2050 <sup>a</sup> 2457 <sup>a</sup>
Provided urine sample	N=67	N=3	1034 1105 <sup>a</sup> 1155	N=81	N=2	2050 <sup>a</sup> 2457 <sup>a</sup>

NA; not applicable.

<sup>a</sup> Lost to follow-up.

**S2 Table. Cure and intensity reduction rates after one, two, three and four treatments with PZQ at two-week intervals in school-aged children infected with *S. mansoni* based on triplicate Kato-Katz thick smears from a single stool sample and single point-of-care circulating cathodic antigen (POC-CCA) urine cassette test.**

	Standard treatment group		Intense treatment group		
	First treatment (W0)	First treatment (W0)	Second treatment (W2)	Third treatment (W4)	Fourth treatment (W6)
<b>Kato-Katz</b>	N=70	N=83	N=82	N=82	N=78
Infected children before treatment <sup>a</sup>	70	83	83	83	83
Cured children after treatment <sup>b</sup>	55	64	80	76	69
CR <sup>c</sup>	80.8% (95% CI 69.6-88.6)	80.0% (95% CI 68.8-85.0)	96.0% (95% CI 89.2-98.6)	98.2% (95% CI 91.4-99.7)	86.0% (95% CI 75.4-98.4)
Median EPG <sup>d</sup>					
Before treatment	172	128	128	128	128
After treatment <sup>b</sup>	8 <i>(out of 13 positive)</i>	12 <i>(out of 18 positive)</i>	8 <i>(out of 3 positive)</i>	8 <i>(one positive)</i>	8 <i>(out of 11 positive)</i>
Arithmetic mean EPG					
Before treatment	298.2	242.7	242.7	242.7	242.7
After treatment <sup>b</sup>	46.2	6.0	0.3	0.1	3.2
IRR <sup>e</sup>	95.6% (95% CI 90.4-98.0)	97.1% (95% CI 94.1-98.6)	99.9% (95% CI 99.7-100.0)	100.0% (95% CI 99.9-100.0)	95.1% (95% CI 85.1-98.4)
<b>POC-CCA (traces considered negative)</b>					
Infected children before treatment <sup>a</sup>	70	83	83	83	83
Cured children after treatment <sup>b</sup>	18	20	30	29	29
CR <sup>c</sup>	20.9% (95% CI 15.0-28.4)	23.2% (95% CI 16.6-31.3)	44.4% (95% CI 35.5-53.7)	47.7% (95% CI 38.8-56.7)	35.7% (95% CI 26.4-46.1)
Median G-score <sup>d</sup>					
Before treatment	6	7	7	7	7
After treatment <sup>b</sup>	6	6	5	5	6
Arithmetic mean G-score					
Before treatment	6.4	6.3	6.3	6.3	6.3
After treatment <sup>b</sup>	5.4	5.7	4.7	4.2	4.6
IRR <sup>f</sup>	15.6%	9.5%	25.4%	33.3%	27.0%

<sup>a</sup> Number of infected children at baseline

<sup>b</sup> Measured 2 weeks post-treatment for one, two and three treatments and measured 4 weeks post-treatment for four treatments

<sup>c</sup> CR as calculated from the model based on the probability of being cured

<sup>d</sup> Median of the positives

<sup>e</sup> IRR based on the reduction in mean EPG as calculated from the model

<sup>f</sup> IRR based on the reduction in mean POC-CCA G-score as calculated manually

Abbreviations: CR, cure rate; EPG, eggs per gram of stool; IRR, intensity reduction rate; POC-CCA, point-of-care circulating cathodic antigen test.